Loading...
01/11 03:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. The partnership with Thermo Fisher and new product launches are positive, but macroeconomic headwinds and uncertainties in government funding pose risks. The financial performance shows modest revenue growth and a reduced net loss, but free cash flow loss remains significant. The share repurchase program is a positive signal, but concerns about academic spending persist. Overall, the sentiment is neutral due to balanced positive and negative factors, with no decisive catalyst to drive strong stock movement.
Revenue $4.1 million, representing 2% year-over-year growth. The increase was primarily due to higher product and service revenue.
Product Revenue $2.8 million, consisting of sales of Proteograph instruments and consumable kits. Despite continued pressure on CapEx budgets and elongated sales cycles, there was continued traction in instrument shipments and consumable kit purchases.
Service Revenue $1.2 million, including $300,000 of related party revenue. This primarily consisted of revenue related to STAC service projects. More than 2/3 of instrument shipments in the quarter were acquired by customers who had previously accessed STAC.
Other Revenue $152,000, consisting of lease and shipping revenue.
Gross Profit $2.1 million, representing a gross margin of 51%, compared to $1.9 million and a gross margin of 48% in the third quarter of 2024. The increase was driven by higher consumable and service revenue.
Operating Expenses $21.5 million, including $3.5 million of stock-based compensation, a decrease of 18% compared to $26.3 million, including $6.1 million of stock-based compensation in the third quarter of 2024. The decrease was primarily due to reductions in stock-based compensation and allocated costs.
Research and Development Expenses $10.8 million, a decrease of 17% compared to $13 million in the third quarter of 2024. The decrease was primarily due to reductions in stock-based compensation and allocated costs.
Selling, General and Administrative Expenses $10.7 million, a decrease of 20% compared to $13.3 million in the third quarter of 2024. The decrease was primarily due to reductions in stock-based compensation and business expenses.
Net Loss $18.2 million, compared to $21.3 million in the third quarter of 2024.
Free Cash Flow Loss Approximately $35.1 million for the 9 months ended September 30, 2025.
Share Repurchase Approximately 1 million Class A common shares repurchased in the third quarter of 2025 at an average price of $1.99 per share. Since May 2024, approximately 11.7 million Class A common shares have been repurchased at a VWAP of $1.87 per share, utilizing approximately $21.9 million of the $25 million share repurchase program authorization. This reduced net total shares outstanding by approximately 14%.
Cash, Cash Equivalents, and Investments Approximately $251 million as of September 30, 2025.
Proteograph ONE Assay and SP200 Automation Instrument: Launched in June, it doubled throughput to over 1,000 samples per week, improved precision, and reduced run time by 30%. Strong demand and utilization observed, with 2/3 of instruments shipped this year being SP200s.
Large-scale studies: Multiple customers initiated large-scale studies, including a 20,000 sample population study with Korea University and a 10,000 sample project with Discovery Life Sciences. Proteograph was also selected for a large NIH-funded multiomic study.
Partnership with Thermo Fisher Scientific: Expanded partnership led to the first joint sale in Q3, aiming to drive adoption of the Proteograph Product Suite.
Instrument shipments: Shipped nearly 3x as many instruments in the first 9 months of 2025 compared to all of 2024. Over half of these were through the Strategic Instrument Placement Program (SIPP).
Seer Technology Access Center (STAC): More than 2/3 of Q3 instrument shipments were acquired by customers who had previously accessed STAC, reflecting its role in driving adoption.
Share repurchase program: Repurchased approximately $22 million of Class A common shares, reducing net total shares outstanding by 14%.
Seer Insights Grant Program: Received 88 applications in 2025, more than double the previous year. Launched an additional program focused on translational researchers.
Shifting government policies around tariffs and research funding: Uncertainty and capital spending constraints on customers due to changing government policies and tariffs, as well as research funding challenges.
Government shutdown: Escalating uncertainty around budgets and availability of funding for customers, particularly affecting NIH funding.
Pressure on CapEx budgets and elongated sales cycles: Customers face budget constraints and longer decision-making processes for purchasing new instruments, impacting sales.
Macroeconomic environment: General economic conditions are creating challenges for capital expenditure and customer spending.
NIH budget uncertainty: Ongoing uncertainty in NIH funding, which is critical for research and customer projects, poses risks to revenue and operations.
Dependence on large-scale studies and partnerships: Reliance on large-scale studies and partnerships for revenue growth, which may be impacted by external factors like funding and economic conditions.
Revenue Guidance: Seer expects revenue for 2025 to be in the range of $17 million to $18 million, representing a 24% growth at the midpoint over 2024. However, the company anticipates revenue to likely be in the lower half of this range due to ongoing macroeconomic pressures, including budget constraints and uncertainty around government funding, particularly related to the NIH.
Impact of Government Shutdown: The company has not factored in additional impacts from the government shutdown. If the shutdown continues for an extended period, it may delay grant funding and potentially impact instrument and consumable shipments in Q4 2025.
Gross Margin Outlook: Seer expects long-term gross margins to be in the range of 70% to 75%, though variability is anticipated on a quarter-by-quarter basis due to fluctuations in the proportion of instrument, consumable, and service revenue.
Cash Flow Breakeven: The company believes it has sufficient capital to reach cash flow breakeven with its current cash, cash equivalents, and investments of approximately $251 million as of September 30, 2025.
Market Trends and Adoption: Seer is seeing increased adoption of its Proteograph technology, with strong demand for the Proteograph ONE Assay and SP200 Automation Instrument launched in June 2025. The company expects these products to drive future revenue growth, supported by large-scale studies and partnerships.
Strategic Partnerships: The expanded partnership with Thermo Fisher Scientific is progressing well, with the first joint sale completed in Q3 2025. This partnership is expected to drive additional adoption of the Proteograph Product Suite over time.
Share Repurchase Program: Seer has repurchased approximately $22 million of its Class A common shares under a $25 million share repurchase program authorized in May 2024. This has reduced the net total shares outstanding by approximately 14%. In the third quarter of 2025, Seer repurchased approximately 1 million Class A common shares at an average price of $1.99 per share. Since the program's inception, approximately 11.7 million Class A common shares have been repurchased at a VWAP of $1.87 per share, utilizing $21.9 million of the authorized amount.
The earnings call presents a mixed outlook. The partnership with Thermo Fisher and new product launches are positive, but macroeconomic headwinds and uncertainties in government funding pose risks. The financial performance shows modest revenue growth and a reduced net loss, but free cash flow loss remains significant. The share repurchase program is a positive signal, but concerns about academic spending persist. Overall, the sentiment is neutral due to balanced positive and negative factors, with no decisive catalyst to drive strong stock movement.
The earnings call summary and Q&A highlight positive aspects such as strong revenue growth, successful product launches, and a strategic partnership with Thermo Fisher. Despite modest current revenue from the partnership, expectations are positive for future growth. The share repurchase program reflects confidence in the company's value. While there are concerns about gross margin decreases and free cash flow losses, the overall sentiment is positive, especially with optimistic guidance and strategic initiatives like STAC. Considering these factors, the stock price is likely to see a positive movement in the short term.
The earnings call indicates mixed signals: revenue and gross profit have increased, and expenses have decreased, which are positive signs. However, significant uncertainties remain due to macroeconomic volatility, regulatory issues, and competitive pressures. The Q&A reveals management's lack of clarity on certain projects and market trends, adding to the uncertainty. Despite a share repurchase program, the overall sentiment is neutral due to the balance of positive financial performance against ongoing risks and uncertainties.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
